Literature DB >> 14508080

E2F1 as a target: promoter-driven suicide and small molecule modulators.

William G Kaelin1.   

Abstract

Decreased requirements for mitogens and diminished sensitivity to antiproliferative signals are among the hallmarks of human cancer. These attributes are due, at least partly, to mutations that directly or indirectly compromise the function of the retinoblastoma tumor suppressor protein (pRB), which is a negative regulator of a family of cell-cycle regulatory transcription factors referred to generically as E2F. Activation of E2F target genes is sufficient to induce unscheduled cellular proliferation but, under certain circumstances, can also lead to programmed cell death (apoptosis). This chapter will review the role of E2F in cancer and outline opportunities for the development of anticancer agents based on E2F biology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508080

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

Review 1.  E2F1: a promising regulator in ovarian carcinoma.

Authors:  Lei Zhan; Yu Zhang; Wenyan Wang; Enxue Song; Yijun Fan; Bing Wei
Journal:  Tumour Biol       Date:  2016-01-09

2.  Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.

Authors:  Xiaoqi Xie; John E Kerrigan; Tamara Minko; Olga Garbuzenko; Kuo-Chieh Lee; Alex Scarborough; Emine Ercikan Abali; Tulin Budak-Alpdogan; Nadine Johnson-Farley; Debabrata Banerjee; Kathleen W Scotto; Joseph R Bertino
Journal:  Cancer Biol Ther       Date:  2013-06-03       Impact factor: 4.742

Review 3.  E2F transcription factors and digestive system malignancies: how much do we know?

Authors:  Athanasios Xanthoulis; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

4.  Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas.

Authors:  Michalis Liontos; Katerina Niforou; Georgia Velimezi; Konstantinos Vougas; Konstantinos Evangelou; Kalliopi Apostolopoulou; Radek Vrtel; Alexandros Damalas; Panayiotis Kontovazenitis; Athanassios Kotsinas; Vassilis Zoumpourlis; George Th Tsangaris; Christos Kittas; Doron Ginsberg; Thanos D Halazonetis; Jiri Bartek; Vassilis G Gorgoulis
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

5.  A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts.

Authors:  Xiaoqi Xie; Nitu Bansal; Tazeem Shaik; John E Kerrigan; Tamara Minko; Olga Garbuzenko; Emine Ercikan Abali; Nadine Johnson-Farley; Debabrata Banerjee; Kathleen W Scotto; Joseph R Bertino
Journal:  Oncotarget       Date:  2014-02-28

6.  The stress of coping with E2F loss.

Authors:  Ainhoa Iglesias-Ara; Ana M Zubiaga
Journal:  Mol Cell Oncol       Date:  2015-05-26

Review 7.  Therapeutic landscape in mutational triple negative breast cancer.

Authors:  Yaqin Shi; Juan Jin; Wenfei Ji; Xiaoxiang Guan
Journal:  Mol Cancer       Date:  2018-07-14       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.